• 不 限
  • 期刊论文
  • 硕博论文
  • 会议论文
  • 报 纸
  • 英文论文
  2. 您的位置
  3. 首页
  4. 会议论文
  5. COMPARISON OF ENTECAVIR MONOTHERAPY AND DE NOVO LAMIVUDINE AND ADEFOVIR COMBINATION THERAPY IN HBEAG

COMPARISON OF ENTECAVIR MONOTHERAPY AND DE NOVO LAMIVUDINE AND ADEFOVIR COMBINATION THERAPY IN HBEAG

来源 :2014年APASL专题会议暨第四届乙型病毒性肝炎专题会议 | 被引量 : 0次 | 上传用户：yan983524
【摘 要】
：
Aims:This study aimed to compare virological response of entecavir monotherapy and de novo lamivudine plus adefovir combination therapy in chronic hepatitis B(CHB) patients with high viral load.
【作 者】
：
Shaohang Cai Tao Yu Yegui Jiang Yonghong Zhang Fangfang Lv Jie Peng 
【机 构】
：
Department of Infectious Diseases,Nanfang Hospital,Southern Medical University,Guangzhou,Guangdong P
【出 处】
：
2014年APASL专题会议暨第四届乙型病毒性肝炎专题会议
【发表日期】
：
2014年4期
下载到本地 , 更方便阅读
下载此文 赞助VIP
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
Aims:This study aimed to compare virological response of entecavir monotherapy and de novo lamivudine plus adefovir combination therapy in chronic hepatitis B(CHB) patients with high viral load.
其他文献
Analysis of pre-existing drug resistance mutations might-related to tenofovir in patients with chron
Background:We amplified and analyzed the hepatitis B virus(HBV) reverse transcriptase(RT) sequences of 75 Chinese patients with chronic hepatitis B who have been treated with nucleos(t)ide analogues e
会议
The factors affecting HBeAg seroconversion of initial treatment with nucleoside analogue among HBeAg
Background:The aim of this study is to analysis the factors affecting HBeAg seroconversion of initial treatment using nucleoside analogue among HBeAgpositive patients.
会议
NFATC3 exerts anti-tumor and anti-viral dual function in hepatitis B virus-related hepatocellular ca
Background:The nuclear factor of activated T-cells,cytoplasmic 3(NFATC3)belongs to a family of transcription factors that can orchestrate an effective immune response mainly in T cells.But the functio
会议
A Model to Estimate Survival in Hepatitis B Virus Related Acute-on-Chronic Liver Failure Patients Ba
Background:Acute-on-chronic liver failure(ACLF)caused by hepatitis B virus(HBV)is a severe disease with high mortality.We aimed to develop a survival model for HBV-related ACLF based on dynamic change
会议
Baseline Prognostic Factors and Statistic Model to Predict Early Virological Response in Lamivudine-
Background:Hepatitis B virus(HBV)infection is still a worldwide disease which may cause liver cirrhosis or even hepatocellular carcinoma.Lamivudine is a potent nucleoside analogue used in treating chr
会议
Risk factor of biliary system infection after PTCD in malignant obstructive jaundice
Background:A retrospective one-center study was conducted to assess the information of bile culture and susceptibility testing special for malignant biliary obstruction and to get the risk factors of
会议
Identification of hepatitis B virus integration in human hepatocellular carcinoma cell lines by HBV-
Background:To investigate the integration role of hepatitis B virus(HBV)on human hepatocellular carcinoma(HCC)cell lines Methods:HCC cell lines from patients with HBV infection(MHCC97H,MHCC97L,MHCCLM3
会议
Evolutionary patterns of hepatocyte hepatitis B virus cccDNA quasispecies under lamivudine treatment
Background:To investigate the evolution of hepatitis B virus(HBV)quasispecies(QS)within the covalently closed circular viral DNA(cccDNA)Polymerase(P)region in hepatocyte during the stage of meeting th
会议
Association between the IKB kinase β and Hepatitis B Virus Infection
Background:The interplay of virus/host proteins mediates the hepatitis B virus(HBV) infection.Host factors may provide new targets for the antiviral therapy of HBV infection.Autophagy plays a vital ro
会议
COMPARISONOFTELBIVUDINEAND ENTECAVIR TREATMENT IN CHRONIC HEPATITIS B PATIENTS WITH PREVIOUS INTERFE
Objective:To evaluate the antiviral efficacy and safety of telbivudine(LDT) and entecavir(ETV) in patients with chronic hepatitis B(CHB) after IFN treatment failure.
会议